Project Grant R21HL184087
Award Date 5/15/26
Completion Date 4/30/28
Dollars Obligated $448K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Syracuse, NY 13210, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $744,880 to the University of Colorado-Denver through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a four-year research project running from September 1, 2025, through May 31, 2029. The research investigates epimetabolic regulation of macrophage activation during acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), focusing on how lactate produced by...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...
- Federal Project Grant Award Summary Temple University received a $498,000 project grant award dated August 16, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a three-year research initiative (through July 31, 2028) led by Principal Investigator Zhengjie Zhou, Ph.D., to develop targeted messenger RNA (mRNA) therapies for treating acute respiratory distress syndrome (ARDS). The research focuses...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a $586,866 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective May 15, 2026, through February 28, 2030. The research investigates the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress syndrome—life-threatening inflammatory conditions frequently caused by sepsis...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $791,503 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion scheduled for June 30, 2029. The award funds research to identify novel roles and therapeutic potential of Protease Activated Receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS). The...
- Federal Project Grant Award Summary Florida International University received a $516,250 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through July 31, 2027. The award supports the development of novel RhoA nitration inhibitory peptides for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research addresses a critical unmet medical need, as...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $1.537 million, effective September 1, 2025, through March 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports basic research on posttranscriptional modification in lung development and regeneration, investigating how methyltransferase-like 3/14 (METTL3/14) complex-mediated RNA...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $189,000 Project Grant to the University of Colorado-Denver for a two-year research initiative (August 1, 2025 – July 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports research investigating the role of aldehyde dehydrogenase 2 (ALDH2) in the pathogenesis and resolution of fibroproliferative acute respiratory distress syndrome (FP-ARDS). The research builds on...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,387 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through April 30, 2029, funds research investigating lung vascular Group 3 Innate Lymphoid Cell (ILC3) subpopulations and their roles in antibacterial immunity and vascular regeneration. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,479,335 Project Grant to Massachusetts Institute of Technology (MIT) on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop advanced analytical and machine learning methodologies for acute respiratory distress syndrome (ARDS) research. The project will deliver target trial emulation studies using observational data and G-methods for causal inference...